The patent describes the extraction and standardization of stable doses of psychedelic compounds VANCOUVER, BC, July 12, 2022 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development company, today announced that it has been issued a third patent by the United States Patent and Trademark Office (USPTO)…


Previous articlePT336 – Sisi Li, Ph.D. – Porta Sophia: Psychedelic Prior Art
Next articlePharmaTher Announces Notice of Allowance for U.S. Patent Covering Ketamine for the Potential Treatment of Parkinson’s Disease and Motor Disorders